Tumor conspicuity significantly correlates with postoperative recurrence in patients with pancreatic cancer: a retrospective observational study

Yoo, Hye Jin; You, Myung‐Won; Han, Dong Yoon; Hwang, Ji Hye; Park, Seong Jin

doi:10.1186/s40644-020-00321-2

Cited by 6 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymph-node metastasis is an important pancreatic carcinoma transfer pathway; it is confirmed by postoperative pathological examination in about 60% of patients[ 16 ]. It has also been recognized as an independent predictor of postoperative recurrence[ 17 - 19 ] and a factor affecting the long-term prognosis of patients with pancreatic carcinoma[ 20 ]. The International Study Group on Pancreatic Surgery has published recommendations for the extent and minimum number of retrieved lymph nodes for SLD[ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical value of extended lymphadenectomy in radical surgery for pancreatic head carcinoma at different T stages

Lyu¹,

Wang²,

Liu³

et al. 2022

World J Gastrointest Surg

View full text Add to dashboard Cite

BACKGROUND As the lymph-node metastasis rate and sites vary among pancreatic head carcinomas (PHCs) of different T stages, selective extended lymphadenectomy (ELD) performance may improve the prognosis of patients with PHC. AIM To investigate the effect of ELD on the long-term prognosis of patients with PHC of different T stages. METHODS We analyzed data from 216 patients with PHC who underwent surgery at our hospital between January 2011 and December 2021. The patients were divided into extended and standard lymphadenectomy (SLD) groups according to extent of lymphadenectomy and into T1, T2, and T3 groups according to the 8 th edition of the American Joint Committee on Cancer’s staging system. Perioperative data and prognoses were compared among groups. Risk factors associated with prognoses were identified through univariate and multivariate analyses. RESULTS The 1-, 2- and 3-year overall survival (OS) rates in the extended and SLD groups were 69.0%, 39.5%, and 26.8% and 55.1%, 32.6%, and 22.1%, respectively ( P = 0.073). The 1-, 2- and 3-year disease-free survival rates in the extended and SLD groups of patients with stage-T3 PHC were 50.3%, 25.1%, and 15.1% and 22.1%, 1.7%, and 0%, respectively ( P = 0.025); the corresponding OS rates were 65.3%, 38.1%, and 21.8% and 36.1%, 7.5%, and 0%, respectively ( P = 0.073). Multivariate analysis indicated that portal vein invasion and lymphadenectomy extent were risk factors for prognosis in patients with stage-T3 PHC. CONCLUSION ELD may improve the prognosis of patients with stage-T3 PHC and may be of benefit if performed selectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical value of extended lymphadenectomy in radical surgery for pancreatic head carcinoma at different T stages

Lyu¹,

Wang²,

Liu³

et al. 2022

World J Gastrointest Surg

View full text Add to dashboard Cite

show abstract

“…The factors that contribute to the high recurrence rate of PDA (60%–80%) have yet to be elucidated [ 85 , 86 ]. Organoid technology has shown potential in this regard.…”

Section: Applications Of Organoids In Various Types Of Cancermentioning

confidence: 99%

Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy

Kalyani

Liu

et al. 2021

Cancer Communications

View full text Add to dashboard Cite

Patient-derived cancer cells (PDCs) and patient-derived xenografts (PDXs) are often used as tumor models, but have many shortcomings. PDCs not only lack diversity in terms of cell type, spatial organization, and microenvironment but also have adverse effects in stem cell cultures, whereas PDX are expensive with a low transplantation success rate and require a long culture time. In recent years, advances in three-dimensional (3D) organoid culture technology have led to the development of novel physiological systems that model the tissues of origin more precisely than traditional culture methods. Patient-derived cancer organoids bridge the conventional gaps in PDC and PDX models and closely reflect the pathophysiological features of natural tumorigenesis and metastasis, and have led to new patient-specific drug screening techniques, development of individualized treatment regimens, and discovery of prognostic biomarkers and mechanisms of resistance. Synergistic combinations of cancer organoids with other technologies, for example, organ-on-a-chip, 3D bio-printing, and CRISPR-Cas9-mediated homology-independent organoid transgenesis, and with

show abstract

“…The following are available online at https://www.mdpi.com/article/10 .3390/healthcare9111478/s1, Table S1: The number of pancreatic ductal adenocarcinoma patients (n = 173) in each cancer stage (1)(2)(3)(4) at the time of the study collected from The Cancer Genome Atlas (TCGA). Figure S1: The annual percent changes for the incidence rates of pancreatic cancer patients for the years 1995 to 2011, Figure S2: The annual percent changes for the mortality rates of pancreatic cancer patients for the years 1995 to 2011.…”

Section: Supplementary Materialsmentioning

confidence: 99%

“…While surgical resection remains the only curative treatment available, 80-85% of tumours are diagnosed at late and unresectable stages, with evidence of locally advanced or metastatic disease. For the small proportion of patients that do qualify for surgical care, survival rates are modest -despite numerous benefits observed when studying the early detection of PC [2] -and patients frequently suffer from local recurrence, metachronous metastasis and high tumour chemoresistance following resection, seen in up to 80% of cases [3]. Despite advances in diagnostic technology, the high frequency of late-stage diagnoses, and the associated poor prognosis, is largely attributable to the non-specific early-stage symptoms, the lack of specific and sensitive biomarkers, and the retroperitoneal position of the pancreas that restricts the accessibility of routine checks [4].…”

Section: Introductionmentioning

confidence: 99%

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

et al. 2021

View full text Add to dashboard Cite

Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhibition of CDK4/6 has therefore gained substantial interest in the hope of new and effective therapeutics in multiple cancers, such as advanced metastatic breast cancer. While the use of these agents is encouraging, their potential is yet to be fully explored. In this study we used the GLOBOCAN database to understand the most recent epidemiology of PC, Human Protein Atlas and KEGG to highlight the role, prevalence, and significance on patient survival of CDK4 in PC. We found that CDK4 cannot be used as prognostic in PC and no significant differences were observed between CDK4 expression and the patient’s clinical status, though larger studies, especially concerning CDK4 protein expressions, are required for a more thorough understanding. The use of CDK4/6 inhibitors in PC is still in clinical trials. However, due to only modest improvements observed in the use of single-agent therapies, efforts have focused on combinatorial approaches.

show abstract

Tumor conspicuity significantly correlates with postoperative recurrence in patients with pancreatic cancer: a retrospective observational study

Cited by 6 publications

References 26 publications

Clinical value of extended lymphadenectomy in radical surgery for pancreatic head carcinoma at different T stages

Clinical value of extended lymphadenectomy in radical surgery for pancreatic head carcinoma at different T stages

Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

Contact Info

Product

Resources

About